MedPath

Guy's And ST Thomas' NHS Foundation Trust

Guy's And ST Thomas' NHS Foundation Trust logo
🇬🇧United Kingdom
Ownership
-
Established
1993-01-01
Employees
25
Market Cap
-
Website
https://www.guysandstthomas.nhs.uk/

Clinical Trials

326

Active:40
Completed:115

Trial Phases

5 Phases

Phase 1:21
Phase 2:12
Phase 3:12
+2 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (200 trials with phase data)• Click on a phase to view related trials

Not Applicable
133 (66.5%)
Phase 4
22 (11.0%)
Phase 1
21 (10.5%)
Phase 2
12 (6.0%)
Phase 3
12 (6.0%)

Improving Sedation Practice in Critically Ill Adult Patients Using a Co-designed Sedation Protocol

Not yet recruiting
Conditions
Intensive Care Medicine
Respiratory Distress Syndrome (RDS)
Sedation and Analgesia
ExtraCorporeal Membrane Oxygenation (ECMO)
Sedation for Mechanical Ventilation
Cardiogenic Shock
Opioid Analgesia
Analgesia
First Posted Date
2025-06-24
Last Posted Date
2025-06-24
Lead Sponsor
Guy's and St Thomas' NHS Foundation Trust
Target Recruit Count
120
Registration Number
NCT07032987
Locations
🇬🇧

Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

Effects of Vibrating Mesh Nebulisation in Patients with COPD During Non-invasive Ventilation (VMN-NIV)

Not Applicable
Not yet recruiting
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Non-invasive Ventilation
First Posted Date
2025-03-19
Last Posted Date
2025-03-19
Lead Sponsor
Guy's and St Thomas' NHS Foundation Trust
Target Recruit Count
12
Registration Number
NCT06884228
Locations
🇬🇧

Lane Fox Unit, St Thomas' Hospital, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

Effects of Vibrating Mesh Nebulisation in Patients on Long-term Tracheostomy Ventilation: a Pilot Randomised Crossover Trial

Not Applicable
Not yet recruiting
Conditions
Long-term Tracheostomy Ventilated Patients
First Posted Date
2025-02-19
Last Posted Date
2025-03-03
Lead Sponsor
Guy's and St Thomas' NHS Foundation Trust
Target Recruit Count
12
Registration Number
NCT06834581
Locations
🇬🇧

Lane Fox Unit, St Thomas' Hospital, London, United Kingdom

Ultrasound Prediction of Successful Balloon Assisted AVF Maturation

Not yet recruiting
Conditions
End Stage Renal Disease (ESRD)
Chronic Kidney Disease Requiring Hemodialysis
First Posted Date
2025-01-13
Last Posted Date
2025-01-15
Lead Sponsor
Guy's and St Thomas' NHS Foundation Trust
Target Recruit Count
40
Registration Number
NCT06771973

Assessing the Efficacy of Photodynamic Therapy for Preventing Surgical Site Infections

Not Applicable
Recruiting
Conditions
Surgery
Nasal Disease
Light; Therapy, Complications
First Posted Date
2024-12-13
Last Posted Date
2025-06-15
Lead Sponsor
Guy's and St Thomas' NHS Foundation Trust
Target Recruit Count
80
Registration Number
NCT06731881
Locations
🇬🇧

Guy's Hospital, London, United Kingdom

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 53
  • Next

News

Brainomix's e-Lung AI Technology Validated for Progressive Pulmonary Fibrosis Detection in Boehringer Ingelheim Collaboration

New studies presented at the American Thoracic Society Conference validate Brainomix's FDA-cleared e-Lung technology as a reliable tool for identifying progressive pulmonary fibrosis with greater sensitivity than conventional methods.

New Bone Marrow Test Could Double Survival Rates for Acute Myeloid Leukemia Patients

A groundbreaking UK trial has developed a highly sensitive bone marrow test that can detect returning Acute Myeloid Leukemia up to three months earlier than standard blood tests, potentially doubling survival rates for some patients.

JAK Inhibitors Reduce Thromboembolic Risk in Myeloproliferative Neoplasms Through Novel Mechanisms

A meta-analysis of 23 publications involving 2,198 patients demonstrated that JAK inhibitors significantly reduce thromboembolic events by 48% in myeloproliferative neoplasm patients, with ruxolitinib showing a 59% reduction in polycythemia vera and myelofibrosis.

Pembrolizumab Shows Promise in Advanced Clear Cell Gynecologic Cancer, PEACOCC Trial Reports

Phase 2 PEACOCC trial demonstrates pembrolizumab's efficacy with 42% disease control rate at 12 weeks in previously treated advanced clear cell gynecologic cancer patients.

Avapritinib Approved for Advanced Systemic Mastocytosis, Offering New Hope to Patients

Avapritinib, a novel drug, has been approved for treating advanced systemic mastocytosis (ASM) by the UK's NICE.

© Copyright 2025. All Rights Reserved by MedPath